Japan 2010 Program

Potential discussions for

Glaucoma Research Society Meeting

Kyoto, April 1-3, 2010

  1. Angle closure glaucoma: the important issues

(Friedman, Sihota,Thomas, Tomita, Aung, Park)

  • Mechanisms of angle closure
  • Definitions of angle closure
  • Who should have an iridotomy
  • Cataract and other LPI complications
  • Primary lens extraction for angle closure

2. Worldwide glaucoma management

(Goldberg, Budenz, Sekhar Tuulonen, Robin, Yamamoto)

  • Could we agree on a consensus worldwide therapeutic approach to primary open angle glaucoma and primary angle closure disease?
  • How does the GRS membership view the W.H.O. April, 2009 Geneva report?
  • Can we apply cost-effectiveness criteria to glaucoma therapy without losing safety?
  • Challenges and opportunities for glaucoma care in developing countries?

3.   Long-acting glaucoma drug therapy

(Araie, Wax, Epstein, Kaufman, Lu, Tamm)

  • What research is needed to produce long-lasting IOP lowering?
  • What would be the best drug delivery method?
  • What effect would such therapy have on our approach to glaucoma?
  • Could we develop treatments to lower IOP for 6 months to one year at a time?
  • What new delivery methods have promise? Pharmaco-genomics, receptor mechanism and new potential therapeutics

4. Basic mechanisms of glaucoma damage

    (Martin, Crowston, Gupta, O’Brien, Yu)

  • Role of glia
  • Role of vasculature
  • Role of biomechanical factors
  • Role of mitochondria/oxidative stress/autophagy

5. Non-IOP lowering neuroprotective treatment

    (Danesh-Meyer, Quigley, Mills, Pillunat, Varma)

  • How can studies be designed to show effectiveness more efficiently?
  • What are the most likely candidate agents for neuroprotection now?
  • Why do animal studies not translate into human drug treatments?


6. New tonometers and telemetric IOP measurement

    (Burgoyne, Kuwayama, Brandt, Zeyen)

  • Do any of the new tonometers represent an improvement in management?
  • Which emerging methods for continuous/telemetric tonometry are most promising?
  • What research do we need to link telemetric measurement and control of IOP to progression?
  • Would continuous IOP measurement add valuable information for therapeutic decisions?

7. How can we improve glaucoma surgery?

    (Heuer, Shirato, Jampel, Traverso, Grehn, Khaw  )

  • IOP effectiveness of various methods at long term
  • complications in the long term
  • basic research aspects (including animal models)
  • new methods—any ready for prime time?
  • How can “success” be defined?

 8. Health economics, glaucoma outcomes and progression

    (Lee, Heijl, Douglas, Chauhan, Tuulonen)

  • Can we justify the way we look for and treat glaucoma?
  • What is the outcome of present glaucoma management?
  • Are we performing too many tests, not enough, or the wrong ones?
  • What is the best way to measure progression?

9. Clinical Implications of SD-OCT imaging of the ONH, NFL and retina in glaucoma   

    (Park, Medeiros, Burgoyne, Araie, Garway-Heath, Schuman)

  •  What is new in what we are seeing?
  •  What are the anatomic targets and why?
  •  What are the clinical implications for risk characterization
  •  What are the clinical implications for longitudinal change detection
  •  How should we design studies of diagnostic accuracy (cross-sectional and longitudinal) for imaging devices?

10. Biomarkers

     (Gandolfi, Kee, Ritch, Tanihara, Coleman, Jonas, Richards, Sugiyama, Alward)

  • Factors that influence outcome
  • Secondary glaucomas, exfoliation
  • Gene polymorphisms
  • Measurable serum molecules